Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Not yet recruiting 7Unknown 6Active not recruiting 6Recruiting 5Completed 5Terminated 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4Solid Advanced Tumor 1Lung Neoplasms 1

Interventions

pembrolizumab 555Specimen Handling 459Carboplatin 446Magnetic Resonance Spectroscopy 427Cyclophosphamide 412Cisplatin 404Gemcitabine 314Radiotherapy 313Bevacizumab 310Paclitaxel 300Biopsy 260Drug Therapy 252Capecitabine 241Oxaliplatin 240fludarabine 236Nivolumab 226venetoclax 225Injections 214Docetaxel 203Fluorouracil 201Dexamethasone 186Radiosurgery 172Rituximab 161Pemetrexed 157durvalumab 144Standard of Care 143atezolizumab 139toripalimab 137tislelizumab 137Leucovorin 137

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Interventional × ensartinib × Clear all
NCT06563999 2026-04-21

NUMER

Sun Yat-sen University

Phase 2 Recruiting
120 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07354061 2026-04-01

TD-ENSEMBLE

Tang-Du Hospital

Phase 1/2 Recruiting
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07448116 2026-03-04

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Betta Pharmaceuticals Co., Ltd.

Phase 1/2 Recruiting
164 enrolled

Solid Advanced Tumor

NCT05341583 2024-08-23

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 3 Recruiting
202 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05241028 2023-10-10

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Hebei Medical University Fourth Hospital

Phase 2 Recruiting
80 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡